Rebekah Mackey
Psychiatric/Mental Health · Tulsa, OKNPI 1932898251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 30.6% of the total.
Across 295 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$508
- Johnson & Johnson$484
- E.r. Squibb & Sons, L.L.C.$460
- AbbVie$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,74698%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 135 | $1,489 |
| Teva Pharmaceuticals USA, Inc. | 23 | $508 |
| Johnson & Johnson(2 entities) | 40 | $484 |
| E.r. Squibb & Sons, L.L.C. | 17 | $460 |
| AbbVie | 22 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $340 |
| Otsuka America Pharmaceutical, Inc. | 11 | $323 |
| Alkermes, Inc. | 13 | $242 |
| Supernus Pharmaceuticals, Inc. | 3 | $164 |
| Vanda Pharmaceuticals Inc. | 2 | $143 |
| Indivior Inc. | 5 | $102 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Gilead | 2 | $52 |
| Lundbeck LLC | 2 | $48 |
| Braeburn Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$125
- Fanapt$125
- ABILIFY ASIMTUFII$123
- ABILIFY MAINTENA$123
- COBENFY$122
- VRAYLAR$121
How this compares
$4,865 in reported general payments places this provider in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 44 | $347,635 |
| AustedoDeutetrabenazine | 29 | $184,827 |
| Austedo XrDeutetrabenazine | 17 | $119,966 |
| Invega SustennaPaliperidone Palmitate | 30 | $94,330 |
| Abilify MaintenaAripiprazole | 24 | $63,026 |
| PerserisRisperidone | 13 | $37,883 |
| RexultiBrexpiprazole | 15 | $19,734 |
| FanaptIloperidone | 11 | $12,375 |
| Aripiprazole | 70 | $2,279 |
| Haloperidol Decanoate | 39 | $1,816 |
| Gabapentin | 98 | $1,217 |
| Quetiapine Fumarate | 75 | $1,036 |
| Ziprasidone Hcl | 18 | $959 |
| Olanzapine | 59 | $895 |
| Trazodone Hcl | 74 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,489 | $347,63544 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $508 | $304,79346 claims |
| Johnson & JohnsonInvega Sustenna | $484 | $94,33030 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $323 | $82,76039 claims |
| Indivior Inc.Perseris | $102 | $37,88313 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $143 | $12,37511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Tulsa
- Fernanda CooleyTulsa$16K
- Pramila TraxlerTulsa$12K
- Sabrina ConleyTulsa$10K
- la Maria FolksTulsa$10K
- Emily MooreTulsa$9K
- Caroline LeithnerTulsa$7K
- John StanfordTulsa$5K
- Kari MurphyTulsa$5K
- Jordan GillinghamTulsa$5K
- Jennifer AycockTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.